Refractory gastroesophageal reflux disease - What next?

Journal of Respiratory Diseases

Volumn 28, Issue 10, 2007, Pages 427-435

  Shapiro, Michael ^a   Moore, Anmarie ^b   Fass, Ronnie ^c,d,e  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d The Neuroenteric Clinical Research Group   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

Gastroesophageal reflux; Proton pump inhibitor therapy

Indexed keywords

ANTIDEPRESSANT AGENT; BACLOFEN; COLESTYRAMINE; LANSOPRAZOLE; METOCLOPRAMIDE; OMEPRAZOLE; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DUODENOGASTRIC REFLUX; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; HYPERSENSITIVITY; IMPEDANCE; LOWER ESOPHAGUS SPHINCTER; MORTALITY; MUSCLE RELAXATION; PAIN; PATIENT COMPLIANCE; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID SECRETION; STOMACH EMPTYING; TREATMENT FAILURE; VISCERA;

EID: 35948971086     PISSN: 0194259X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998;10:119-124.
2. Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001;121:1095-1100.
3. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther. 1997;11:765-773.
4. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656-664.
5. Clouse RE, Richter JE, Heading RC, et al. Functional esophageal disorders. In: Drossman DA, Corazziari E, Talley NJ, et al, and the Rome II International Working Teams, eds. Rome II: The Functional Gastrointestinal Disorders. 2nd ed. Lawrence, Kan: Allen Press, Inc; 2000:275.
6. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997;32:974-979.
7. Fass R, Sampliner RE. Barrett's oesophagus: optimal strategies for prevention and treatment. Drugs. 2003;63:555-564.
8. Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537-545.
9. Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther. 1998;12:893-897.
10. Fass R, Sampliner RE, Malagon IB, et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther. 2000;14:597-602.
11. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol. 1994;89:1844-1848.
12. Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc. 1996;44:700-705.
13. Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract. 1999;49:463-464.
14. The Gallup Organization. Gallup Study of Consumers' Use of Stomach Relief Products. 2000.
15. Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol. 1996;91:1532-1538.
16. Vaezi MF. Duodenogastroesopahgeal reflux. In: Castell DO, Richter JE, eds. The Esophagus. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2004:434-450.
17. Fass R, Ofman JJ. Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol. 2002;97:1901-1909.
18. Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut. 2002;51:885-892.
19. Castell DO, Murray JA, Tutuian R, et al. Review article: the pathophysiology of gastro-oesophageal reflux disease - oesophageal manifestations. Aliment Pharmacol Ther. 2004;20(suppl 9):14-25.
20. Buckles DC, Sarosiek I, McMillin C, McCallum RW. Delayed gastric emptying in gastroesophageal reflux disease: reassessment with new methods and symptomatic correlations. Am J Med Sci. 2004;327:1-4.
21. McCallum RW, Berkowitz DM, Lerner E. Gastric emptying in patients with gastroesophageal reflux. Gastroenterology. 1981;80:285-291.
22. Kudara N, Chiba T, Orii S, et al. Gastric emptying of patients with persistent reflux symptoms and erosive esophagitis under PPI therapy [abstract]. Neurogastroenterol Motil. 2004;16:654. Abstract 23.
23. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol. 2005;100:283-289.
24. Bautista JM, Wong WM, Pulliam G, et al. The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications. Dig Dis Sci. 2005;50:1909-1915.
25. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988;95:903-912.
26. Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy - a prospective, randomized, multi-centre study. Aliment Pharmacol Ther. 2000;14:1595-1603.
27. Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the "sensitive oesophagus." Gut. 1997;40:587-590.
28. Vaezi MF, Richter JE, Stasney ER, et al. A randomized, double-blind, placebo-controlled study of acid suppression for the treatment of suspected laryngopharyngeal reflux [abstract]. Gastroenterology. 2004;126:A-22. Abstract 160.
29. Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut. 2003;52:1397-1402.
30. Clouse RE. Psychotropic medications for the treatment of functional gastrointestinal disorders. Clin Perspect Gastroenterol. 1999;2:348-356.
31. Varia I, Logue E, O'Connor C, et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J. 2000;140:367-372.
32. Prakash C, Clouse RE. Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci. 1999;44:2373-2379.
33. So JB, Zeitels SM, Rattner DW. Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery. 1998;124:28-32.
34. Spechler SJ. The management of patients who have "failed" antireflux surgery. Am J Gastroenterol. 2004;99:552-561.
35. Mainie I, Tutuian R, Agrawal A, et al. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg. 2006;93:1483-1487.
36. Chuttani R, Sud R, Sachdev G, et al. A novel endoscopic full-thickness plicator for the treatment of GERD: a pilot study. Gastrointest Endosc. 2003;58:770-776.
37. Triadafilopoulos G, Dibaise JK, Nostrant TT, et al. Radiofrequency energy delivery to the gastroesophageal junction for the treatment of GERD. Gastrointest Endosc. 2001;53:407-415.
38. Feretis C, Benakis P, Dimopoulos C, et al. Endoscopic implantation of Plexiglas (PMMA) microspheres for the treatment of GERD. Gastrointest Endosc. 2001;53:423-426.